30% of Aggressive Breast Cancer Patients Respond to Sacituzumab Govitecan, Trial Shows

30% of Aggressive Breast Cancer Patients Respond to Sacituzumab Govitecan, Trial Shows

Thirty percent of patients with metastatic triple-negative breast cancer (TNBC) responded to the experimental therapy sacituzumab govitecan after failing to respond to other treatments, according to Phase 2 trial results.

Other measures of its effectiveness included the length of time patients responded to treatment, overall patient survival rate, and time to progression. The therapy was also well-tolerated, the team added.

The study, “Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer,” was published in the Journal of Clinical Oncology.

Sacituzumab govitecan is an antibody-drug conjugate composed of an anti-TROP-2 antibody linked to a toxic payload, SN-38.

TNBC patients, whose tumors lack estrogen and progesterone receptors and do not over-express HER2, lack targeted therapies. Chemotherapy is the current standard of care, but only 15 to 20 percent of patients with metastatic disease respond to it.

Leave a Comment

Your email address will not be published. Required fields are marked *